Specializing In:Thymic malignancies
Research Interests:Personalized therapy in lung cancer Immunotherapy Immune-related adverse events Targeted therapies Prevention of toxicities Drug development Biomarker discovery
About Prantesh Jain
I am a medical oncologist specializing in the treatment of patients with thoracic malignancies, such as lung cancer, thymic malignancies and mesothelioma. I completed my clinical training (fellowship) in adult Hematology-Oncology from the Case Western Reserve University, Cleveland, Ohio, and did a training in clinical research from the National Institutes of Health. Prior to joining fellowship, I served as Clinical Assistant Professor at the Cleveland Clinic Lerner College of Medicine, Department of Internal Medicine. I completed medical school at Kasturba Medical College, Manipal Academy of Higher Education, India, and residency training at John H Stroger Hospital of Cook County, affiliate of Rush University, Chicago.
My research interests include developmental cancer therapeutics and biomarker discovery for precision oncology. Currently my research focus is on the identification and evaluation of novel, predictive and prognostic, image-based biomarkers using high-throughput machine learning algorithms (AI) and multi-omics data integration to enable risk stratification and optimal patient selection (precision oncology) for the treatment of lung cancer. In addition, I am working on developing novel immunotherapeutic treatment strategies and biomarker driven clinical trials. I have presented my work at national and international meetings such as the annual meetings of the American Society of Clinical Oncology (ASCO), International Association for the Study of Lung Cancer (IASLC) and the ECOG-ACRIN Young Investigator Symposium. My work has been published in high impact journals including Journal for ImmunoTherapy of Cancer and ESMO Open, among others. I have peer-reviewed scientific articles for several prestigious journals like Journal of Clinical Oncology-Precision Oncology, Journal for ImmunoTherapy of Cancer, Frontiers in Oncology, PLOS ONE. I am motivated to stimulate collaborative research across multi-disciplinary departments including medicine, bioengineering, computational biology in order to discover composite biomarkers and push the boundaries of personalized medicine.
I have been fortunate to receive several awards including an Early Career Award from the International Association of study of Lung cancer ASLC in 2020, Editorial Fellowship from the ASCO in 2018, and two Cancer Informatics/ “Big Data” grant awards from the University Hospitals Research and Education Institute, Case Western Reserve University in 2019 and 2020. I was selected for the ASCO Virtual Mentoring Program in 2020 and serve as volunteer for the Society’s educational activities. Additionally, I received Humanitarian Awards for exceptional service and patient care at both University Hospitals and the Cleveland Clinic Foundation. Recently, I received the honor and distinction as Fellow of the American College of Physicians (FACP).
I believe that everything we do as doctors is for the patient. Whether that be research or clinical care, my pursuit of academic medicine and clinical research is with the intention of bettering my patients’ lives.
- Assistant Professor of Oncology
- Department of Medicine, Thoracic Oncology
State University of New York at Buffalo
- Clinical Assistant Professor
Education and Training:
- 2009 - Kasturba Medical College, Manipal Academy of Higher Education, Manipal, India
- 2010-2013 - Internal Medicine, John H. Stroger Hospital of Cook County, Rush University, Chicago, IL
- 2018-2021 - Case Western Reserve University, Cleveland, OH
- American Board of Internal Medicine, Internal Medicine
- Society for Immunotherapy for Cancer
- American Association for Cancer Research
- European Society of Medical Oncology
- American Society of Clinical Oncology
- International Association for the Study of Lung Cancer
- 2021-present - Scientific Review Committee, Roswell Park Comprehensive Cancer Center
- 2015-2018 - Clinical Assistant Professor, Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, Cleveland, OH
- 2013-2018 - Clinical Associate, Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH
Honors & Awards:
- Early Career Award, International Association for Study of Lung Cancer
- ASCO Editorial Fellowship for Journal of Clinical Oncology
- ASCO Virtual Mentoring Program, Mentee
- ECOG-ACRIN Young Investigator Symposium, Oral Presentation Award
- World Conference on Lung Cancer, IASLC, Oral Presentation Award
- Cancer Informatics/Big Data Grant Award, University Hospitals Research & Education Institute
- Fellow of the American College of Physicians
- Humanitarian Award for Exceptional Service and Patient Care, University Hospitals Cleveland Medical Center
- Humanitarian Award, Cleveland Clinic Foundation
Jain P, Gutierrez Bugarin J, Guha A, Jain C, Patil N, Shen T, Stanevich I, Nikore V, Margolin K, Ernstoff M, Velcheti V, Barnholtz-Sloan J, Dowlati A. Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States. ESMO Open. 2021 Aug 27;6(5):100252. PMID: 34461483.
Jain P*, Guha A*, Fradley MG, Lenihan D, Gutierrez JM, Jain C, de Lima M, Barnholtz-Sloan JS, Oliveira GH, Dowlati A, Al-Kindi S. Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries. Cancer Med. 2021 Jun;10(12):3862-3872. PMID: 33982883; PMCID: PMC8209554. *co-first author
Jain P*, Khorrami M*, Bera K, Alilou M, Thawani R, Patil P, Ahmad U, Murthy S, Stephans K, Fu P, Velcheti V, Madabhushi A. Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features. Lung Cancer. 2019 Sep;135:1-9. PMID: 31446979; PMCID: PMC6711393. *co-first author
Vaidya P, Bera K, Patil PD, Gupta A, Jain P, Alilou M, Khorrami M, Velcheti V, Madabhushi A. Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade. J Immunother Cancer. 2020 Oct;8(2):e001343. PMID: 33051342; PMCID: PMC7555103.
Lee M, Jain P, Wang F, Ma PC, Borczuk A, Halmos B. MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies. Expert Opin Ther Targets. 2021 Apr;25(4):249-268. doi: 10.1080/14728222.2021.1925648. Epub 2021 Jun 13. PMID: 33945380.